Global 1-Indanone Market Strategic Research Report

Scope of the Report

The global 1-Indanone market size is predicted to grow from US$ 48.16 million in 2025 to US$ 66.23 million in 2032; it is expected to grow at a CAGR of 4.6% from 2026 to 2032.

1-Indanone (CAS 83-33-0) is a white to pale yellow crystalline powder that serves as a key intermediate in pharmaceutical synthesis, particularly as an essential raw material for the anti-HIV drug indinavir and the Parkinson's disease drug rasagiline. Its upstream raw materials mainly consist of the petrochemical derivatives indan and benzene-based compounds. Downstream customers primarily include active pharmaceutical ingredient manufacturers and pharmaceutical companies. In 2025, the global production capacity of 1-indanone is estimated at approximately 5,210 metric tons, with sales volume of around 4,689 metric tons and an average ex-factory price of approximately US$ 10,500 per metric ton. The industry's gross profit margin typically ranges from 16% to 24%, with notable variations among producers of different purity grades and production scales.

Major producers in the global 1-indanone market include JFE Chemical in Japan and several pharmaceutical intermediate companies in China, which together form the supply system for industrial-grade products. Leveraging its petrochemical industry chain and cost characteristics, China holds a certain share in global 1-indanone production. Stable growth in market demand is primarily driven by the sustained production of antiretroviral drugs such as indinavir and the rising demand for Parkinson's disease drugs like rasagiline in aging societies. Meanwhile, the gradual expansion of its applications in fine chemical sectors such as fragrances, dyes, and optoelectronic materials provides diversified support to the industry.

Future technological upgrades will center on green synthesis processes and continuous flow production to address the high chromium pollution and energy intensity of traditional oxidation routes. Research into biocatalytic methods and novel catalytic oxidation systems is advancing, which is expected to enhance production compliance and cost competitiveness under tightening environmental regulations. The post-patent generic drug volume growth will boost demand for high-quality 1-indanone, prompting producers to upgrade product structures toward pharmaceutical grade and higher purity. Furthermore, active exploration of indanone-derived new molecules in antiviral and anti-inflammatory drug research and development will render custom synthesis and contract development and manufacturing services emerging growth highlights for the industry.

Core growth drivers stem from the rigid demand of global chronic disease management. The long-term widespread use of HIV treatments and the increasing number of Parkinson's disease patients due to population aging constitute irreplaceable raw material requirements for 1-indanone. The expansion of generic drug markets leads to continued growth in active pharmaceutical ingredient intermediate procurement, especially as local formulation production capacity in emerging markets further boosts upstream intermediate trade. Moreover, supply chain interactions between China and India in the pharmaceutical intermediate sector help rationalize production costs and improve supply reliability, thereby enhancing overall market accessibility.

The industry still faces notable obstacles. Stricter environmental regulations impose high treatment costs for chromium-containing wastewater from traditional processes, forcing some small-scale producers to face remediation pressure or choose to exit. Price volatility of raw materials indan and benzene-based compounds, largely influenced by international crude oil markets and the downstream aromatics industry chain, brings uncertainty to cost control for producers. Additionally, product applications remain relatively narrow, with excessive reliance on a few mature drugs. If these drugs are replaced by next-generation therapies or see drastic price declines after patent expiration, market demand may experience periodic contraction, highlighting the industry's need for strengthened resilience.

Key Questions Addressed in this Report

What is the 10-year outlook for the global 1-Indanone market?

What factors are driving 1-Indanone market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do 1-Indanone market opportunities vary by end market size?

How does 1-Indanone break out by Type, by Application?

This report presents a comprehensive overview of the global 1-Indanone market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Purity 98%
• Purity 99%
• Others

Segment by Grade

• Industrial Grade
• Pharmaceutical Grade
• Other

Segment by Sales Channel

• Online Sales
• Offline Sales

Segment by Application

• Indinavir Intermediates
• Rasagiline Intermediates
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global 1-Indanone market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Indinavir Intermediates, Rasagiline Intermediates, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact